Fas Deficiency Prevents Type 1 Diabetes by Inducing Hyporesponsiveness in Islet β-Cell−Reactive T-Cells

  1. Luis Vence123,
  2. Christophe Benoist123 and
  3. Diane Mathis123
  1. 1Section on Immunology and Immunogenetics, Joslin Diabetes Center, Boston, Massachusetts
  2. 2Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
  3. 3Harvard Medical School, Boston, Massachusetts
  1. Address correspondence and reprint requests to Drs. Christophe Benoist and Diane Mathis, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215. E-mail: cbdm{at}joslin.harvard.edu

Abstract

Type 1 diabetes is an autoimmune disease wherein autoreactive T-cells promote the specific destruction of pancreatic islet β-cells. Evidence for a crucial role for Fas/FasL interactions in this destruction has been highly controversial because of the pleiotropic effects of Fas deficiency on the lymphoid and other systems. Fas-deficient mice are protected from spontaneous development of diabetes not because Fas has a role in the destruction of β-cells, but rather because insulitis is abrogated. Fas may somehow be involved in the series of events provoking insulitis; for example, it may play a role in the physiological wave of β-cell death believed to result in the export of pancreatic antigens to the pancreatic lymph nodes and, thereby, to circulating, naive, diabetogenic T-cells for the first time. To explore the implication of Fas in these events, we crossed the lpr mutation into the BDC2.5 model of type 1 diabetes to make it easier to monitor direct effects on the pathogenic specificity. We demonstrated that BDC2.5/NODlpr/lpr mice have qualitatively and quantitatively less aggressive insulitis than do BDC2.5/NOD mice. In vitro proliferation assays showed that BDC2.5/NODlpr/lpr splenocytes proliferated less vigorously than those from control mice in the presence of islet extracts, which reflects their inability to produce interleukin-2, resulting in weaker pathogenicity.

Footnotes

  • L.V. is currently affiliated with the Baylor Institute of Immunology Research, Dallas, Texas.

    • Accepted July 16, 2004.
    • Received December 5, 2003.
« Previous | Next Article »Table of Contents